136
Participants
Start Date
February 16, 2021
Primary Completion Date
March 21, 2022
Study Completion Date
March 25, 2022
ACT-539313
ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Placebo
Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Manhattan Behavioral Medicine PLLC, New York
The Medical Research Network, New York
Bioscience Research, Mount Kisco
Psych Atlanta P.C., Marietta
NeuorTrials Research Inc, Atlanta
Clinical Neuroscience Solutions Inc, Orlando
Clinical Neurosciences Solutions, Jacksonville
Behavioral Clinical Research, North Miami
Precise Research Centers, Flowood
North Star Medical Research, LLC, Middleburg Heights
University of Cincinnati College of Medicine - Lindner Center of HOPE, Mason
CTI Clinical Research Center, Cincinnati
Patient Priority Clinical Sites, Cincinnati
Capstone Clinical Research, Libertyville
St. Charles Psychiatric Associates dba Midwest research group, Saint Charles
Collective Medical Research, Prairie Village
IPS Research Company, Oklahoma City
Clinical Trials of Texas, Inc. (CTT), San Antonio
M3 Wake Research, Las Vegas
Southern California Research, Beverly Hills
Wr-Pri, Llc, Encino
Syrentis Clinical Research, Santa Ana
Collaborative Neuroscience Network (CNS), Garden Grove
Oregon Center For Clinical Inv., Portland
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.), Salem
Connecticut Clinical Research - Cromwell, Cromwell
Harvard Medical School - McLean Hospital, Belmont
Boston Clinical Trials, Inc, Boston
ActivMed Practices & Research, Inc., Portsmouth
ActivMed Practices & Research, Portsmouth
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
INDUSTRY